Header Logo

Connection

DOV KADMON to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications DOV KADMON has written about Prostatic Neoplasms.
DOV KADMON
Connection Strength
3.795
Prostatic Neoplasms
  1. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
    View in: PubMed
    Score: 0.201
  2. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.165
  3. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 2007 Dec 15; 110(12):2628-39.
    View in: PubMed
    Score: 0.155
  4. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.141
  5. Long-term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins. J Urol. 2006 Jun; 175(6):2097-101; discussion 2101-2.
    View in: PubMed
    Score: 0.139
  6. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
    View in: PubMed
    Score: 0.136
  7. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol. 2005 Jun; 173(6):1923-5.
    View in: PubMed
    Score: 0.130
  8. Oncologic Outcome of the Extent of Pelvic Lymph Node Dissection During Radical Prostatectomy: A Systematic Review, Meta-analysis, and Network Analysis. Eur Urol Focus. 2024 Mar; 10(2):234-241.
    View in: PubMed
    Score: 0.118
  9. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther. 2001 May; 1(3):481-95.
    View in: PubMed
    Score: 0.098
  10. Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol. 2000 Nov 15; 18(22):3804-8.
    View in: PubMed
    Score: 0.095
  11. Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res. 2000 Oct; 6(10):3845-9.
    View in: PubMed
    Score: 0.094
  12. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70.
    View in: PubMed
    Score: 0.092
  13. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene. World J Urol. 2000 Apr; 18(2):125-9.
    View in: PubMed
    Score: 0.091
  14. Beyond prostate specific antigen--markers for prostate cancer for the 21st Century. J Urol. 2000 Mar; 163(3):828.
    View in: PubMed
    Score: 0.090
  15. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol. 2000 Jan; 18(1):116-21.
    View in: PubMed
    Score: 0.089
  16. Solitary pulmonary metastasis from prostate cancer. J Urol. 1999 Dec; 162(6):2102.
    View in: PubMed
    Score: 0.089
  17. Influence of the neural microenvironment on prostate cancer. Prostate. 2018 Feb; 78(2):128-139.
    View in: PubMed
    Score: 0.077
  18. Histologic features of stromogenic carcinoma of the prostate (carcinomas with reactive stroma grade 3). Hum Pathol. 2017 05; 63:202-211.
    View in: PubMed
    Score: 0.073
  19. Intracranial metastases as the first manifestation of prostate cancer. Urology. 1996 Nov; 48(5):789-93.
    View in: PubMed
    Score: 0.072
  20. Pitfalls in interpreting prostate specific antigen velocity. J Urol. 1996 May; 155(5):1655-7.
    View in: PubMed
    Score: 0.069
  21. Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
    View in: PubMed
    Score: 0.058
  22. Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO). J Cell Biochem Suppl. 1992; 16H:122-7.
    View in: PubMed
    Score: 0.051
  23. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol. 1991 Aug; 146(2):358-61.
    View in: PubMed
    Score: 0.050
  24. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan; 178(1):79-87.
    View in: PubMed
    Score: 0.048
  25. Imaging prostate derived tumors with PET and N-(3-[18F]fluoropropyl)putrescine. Int J Rad Appl Instrum B. 1990; 17(6):525-32.
    View in: PubMed
    Score: 0.045
  26. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2010 Mar; 13(1):6-11.
    View in: PubMed
    Score: 0.043
  27. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis. 2009; 12(3):301-9.
    View in: PubMed
    Score: 0.042
  28. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603.
    View in: PubMed
    Score: 0.041
  29. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res. 2008 Feb 01; 68(3):731-9.
    View in: PubMed
    Score: 0.039
  30. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov; 38(11):1611-20.
    View in: PubMed
    Score: 0.038
  31. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007 Nov; 38(11):1688-95.
    View in: PubMed
    Score: 0.038
  32. Preliminary report of the effect of high-dose adjuvant intensity modulated radiation therapy on the sural nerve graft for cavernosal nerve sacrifice after radical prostatectomy. Am J Clin Oncol. 2007 Aug; 30(4):395-400.
    View in: PubMed
    Score: 0.038
  33. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27.
    View in: PubMed
    Score: 0.038
  34. alpha-Difluoromethylornithine enhancement of 14C-putrescine uptake by an androgen-dependent prostatic tumor. J Urol. 1986 Oct; 136(4):944-8.
    View in: PubMed
    Score: 0.036
  35. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36.
    View in: PubMed
    Score: 0.034
  36. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 2006 Jan; 5(1):78-83.
    View in: PubMed
    Score: 0.034
  37. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol. 2005 Jul; 48(1):153-61.
    View in: PubMed
    Score: 0.032
  38. Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. Urology. 2005 Jan; 65(1):131-5.
    View in: PubMed
    Score: 0.032
  39. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18.
    View in: PubMed
    Score: 0.032
  40. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol. 2004 Sep; 172(3):900-4.
    View in: PubMed
    Score: 0.031
  41. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
    View in: PubMed
    Score: 0.030
  42. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol. 2004 May; 171(5):1850-4.
    View in: PubMed
    Score: 0.030
  43. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
    View in: PubMed
    Score: 0.030
  44. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol. 2004 Mar; 171(3):1089-92.
    View in: PubMed
    Score: 0.030
  45. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol. 2004 Jan; 171(1):204-9.
    View in: PubMed
    Score: 0.029
  46. Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003 Apr; 4(3):251-61.
    View in: PubMed
    Score: 0.028
  47. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96.
    View in: PubMed
    Score: 0.027
  48. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function. Int J Radiat Oncol Biol Phys. 2002 Sep 01; 54(1):101-6.
    View in: PubMed
    Score: 0.027
  49. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol. 1982 Jun; 127(6):1238-42.
    View in: PubMed
    Score: 0.026
  50. Gene therapy for prostate cancer. Expert Rev Anticancer Ther. 2002 Jun; 2(3):309-21.
    View in: PubMed
    Score: 0.026
  51. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66.
    View in: PubMed
    Score: 0.026
  52. Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology. 2001 Dec; 58(6):983-7.
    View in: PubMed
    Score: 0.025
  53. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
    View in: PubMed
    Score: 0.025
  54. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
    View in: PubMed
    Score: 0.025
  55. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001 May; 165(5):1554-9.
    View in: PubMed
    Score: 0.024
  56. In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol Ther. 2001 Apr; 3(4):500-6.
    View in: PubMed
    Score: 0.024
  57. Effect of surgery and adjuvant chemotherapy on the R3327 MAT-Ly Lu tumor. Prostate. 1981; 2(3):299-307.
    View in: PubMed
    Score: 0.024
  58. Gene therapy for prostate cancer. Urology. 2001 Jan; 57(1):8-16.
    View in: PubMed
    Score: 0.024
  59. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol. 2000 Jun; 163(6):1747-50.
    View in: PubMed
    Score: 0.023
  60. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis. 2000; 18(5):429-38.
    View in: PubMed
    Score: 0.022
  61. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998 Aug; 52(2):195-201; discussion 201-2.
    View in: PubMed
    Score: 0.020
  62. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene. 1995 Mar 02; 10(5):869-79.
    View in: PubMed
    Score: 0.016
  63. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 1995 Mar; 45(3):491-7.
    View in: PubMed
    Score: 0.016
  64. Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc Res Tech. 1995 Mar 01; 30(4):333-41.
    View in: PubMed
    Score: 0.016
  65. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol. 1995; 13(6):324-8.
    View in: PubMed
    Score: 0.016
  66. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res. 1993 Oct 01; 53(19):4461-5.
    View in: PubMed
    Score: 0.014
  67. Transgenic models for the study of prostate cancer. Cancer. 1993 Feb 01; 71(3 Suppl):1165-71.
    View in: PubMed
    Score: 0.014
  68. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol. 1993 Jan; 24(1):4-9.
    View in: PubMed
    Score: 0.014
  69. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog. 1993; 7(3):165-79.
    View in: PubMed
    Score: 0.014
  70. Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas. J Steroid Biochem Mol Biol. 1992 Sep; 43(1-3):79-85.
    View in: PubMed
    Score: 0.013
  71. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl. 1992; 16H:54-61.
    View in: PubMed
    Score: 0.013
  72. Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol Carcinog. 1992; 5(1):52-61.
    View in: PubMed
    Score: 0.013
  73. Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol. 1991 Apr; 5(4):503-13.
    View in: PubMed
    Score: 0.012
  74. Experimental oncogene induced prostate cancer. Cancer Surv. 1991; 11:55-71.
    View in: PubMed
    Score: 0.012
  75. N-3-[18F]fluoropropylputrescine as potential PET imaging agent for prostate and prostate derived tumors. J Nucl Med. 1989 Jul; 30(7):1205-10.
    View in: PubMed
    Score: 0.011
  76. Differential effect of alpha-difluoromethylornithine on the in vivo uptake of 14C-labeled polyamines and methylglyoxal bis(guanylhydrazone) by a rat prostate-derived tumor. Cancer Res. 1984 Mar; 44(3):1034-40.
    View in: PubMed
    Score: 0.007
  77. Prostatic cancer, acid phosphatase, creatine kinase-BB and race: a prospective study. J Urol. 1982 Oct; 128(4):735-8.
    View in: PubMed
    Score: 0.007
  78. Growth inhibition of a prostate tumor by alpha-difluoromethylornithine and by cyclophosphamide. Cancer Lett. 1982 May-Jun; 16(1):71-79.
    View in: PubMed
    Score: 0.007
  79. Inhibition of the R3327MAT-Lu prostatic tumor by diethylstilbestrol and 1,2-bis(3,5-dioxopiperazin-1-yl)propane. Cancer Res. 1982 Apr; 42(4):1390-4.
    View in: PubMed
    Score: 0.007
  80. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine. Prostate. 1982; 3(4):383-9.
    View in: PubMed
    Score: 0.006
  81. Effect of high dose diethylstilbestrol and ICRF-159 on the growth and metastases of the R3327 MAT-LyLu prostate-derived tumor. Cancer Lett. 1981 Jul; 13(2):139-45.
    View in: PubMed
    Score: 0.006
  82. Surgical considerations in treatment of intraductal carcinoma of the prostate. J Urol. 1978 Aug; 120(2):259-61.
    View in: PubMed
    Score: 0.005
  83. Effect of mini-dose heparin on lymphocele formation following extraperitoneal pelvic lymphadenectomy. J Urol. 1980 Jun; 123(6):890-2.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.